In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European IVD Companies See Worrying Trend In Market Access Barriers

Executive Summary

Are medtech regulators and authorities in wider Europe – including Russia – setting market access barriers too high, risking investment in innovation and potentially denying patients access to modern care? European Diagnostic Manufacturers Association (EDMA) representative Christian Parry fears so, in this second half of our industry update from the 2015 European MedTech Forum.

You may also be interested in...



Uncertain Reg Climate Could Turn Medtech Investors Off Europe

A key stage in the EU process of adopting and implementing new regulations for medical devices and diagnostics was reached with the recent series of debates – the Trilogues – between the European Commission, the Parliament and Council of the EU. But matters are poised on a knife edge and are not always moving as quickly as or in the way local industry wants.

Start-Up Spotlight: Pre Diagnostics Picks Up Momentum In Early Neurodegenerative Disease Detection

Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.

Turkey’s Updated Medtech Advertising Regulations Will Assist Traceability

Device sales centers are being required to update the government’s product tracking system with sales data under a series of recent changes spurred partly by COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel